Randomized controlled phase IV trial of combination aflibercept and Kallidinogenase for neovascular age-related macular degeneratio
Not Applicable
- Conditions
- Age-related macular degeneration
- Registration Number
- JPRN-UMIN000011703
- Lead Sponsor
- Mie University Graduate School of Medicine Department of Ophthalmology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1)internal use of kallidinogenase 2)intravitreal anti-VEGF therapy or intravitreal steroid therapy in the study eye within the past 6 months 3)photodynamic therapy or focal laser in the study eye within the past 6 months 4)surgical therapy in the study eye within the past 6 months 5)past allergic reaction for kallidinigenase 6)pregnancy (positive pregnancy test) women 7)participation in another simultaneous medical investigation or trial within the past 3 months 8)other conditions that the investigator believed would pose a significant hazard to the subject if investigational therapy were initiated
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method central retinal thickness
- Secondary Outcome Measures
Name Time Method